Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunology
Researchers from King Faisal Specialist Hospital and Research Center discuss findings in cancer vaccines immunology
March 10th, 2009
New investigation results, 'Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue,' are detailed in a study published in Leukemia & Lymphoma. "The Wilms tumor antigen 1 (WT1) antigen is over-expressed in human leukemias, making it an attractive target for immunotherapy. Most WT1-specific Cytotoxic T Lymphocytes (CTLs) described so far displayed low avidity, limiting its function," investigators in Riyadh, Saudi Arabia report. "To improve the immunogenicity of CTL epitopes, we replaced the first-amino-acid of two known immunogenic WT1-peptides (126 and 187) with a tyrosine. This modification...
Source: Cancer Weekly (2009-03-10)
|
